On the stock market since 2020, it operates in the world of health and science. It has 1,838 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 18% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $253.9M a year. A small number, but proof the product has real buyers.
There is $128.8M in the vault; even if every debt were paid off, $59.6M would remain.
It pays out $0.12 per share each year — regular cash for whoever holds the stock.
A loss of $60.4M against $253.9M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.
On our five-subject report card, TKBIF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: TKBIF is a high-risk stock — not yet profitable, and its future rides on its product catching on.